These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

650 related articles for article (PubMed ID: 29562227)

  • 1. Anti-Angiogenics: Their Value in Colorectal Cancer Therapy.
    Seeber A; Gunsilius E; Gastl G; Pircher A
    Oncol Res Treat; 2018; 41(4):188-193. PubMed ID: 29562227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Anti-angiogenic treatments in metastatic colorectal cancer: Does a continuous angiogenic blockade make sense?].
    Jary M; Borg C; Bouché O; Kim S; André T; Bennouna J
    Bull Cancer; 2015 Sep; 102(9):758-71. PubMed ID: 26232849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-Angiogenics: Their Value in Lung Cancer Therapy.
    Janning M; Loges S
    Oncol Res Treat; 2018; 41(4):172-180. PubMed ID: 29631257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-Angiogenics: Current Situation and Future Perspectives.
    Zirlik K; Duyster J
    Oncol Res Treat; 2018; 41(4):166-171. PubMed ID: 29562226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-Angiogenics: Their Role in the Treatment of Glioblastoma.
    Winkler F; Osswald M; Wick W
    Oncol Res Treat; 2018; 41(4):181-186. PubMed ID: 29562225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-angiogenic therapies for metastatic colorectal cancer.
    Wagner AD; Arnold D; Grothey AA; Haerting J; Unverzagt S
    Cochrane Database Syst Rev; 2009 Jul; (3):CD005392. PubMed ID: 19588372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature.
    Pohl M; Werner N; Munding J; Tannapfel A; Graeven U; Nickenig G; Schmiegel W; Reinacher-Schick A
    Z Gastroenterol; 2011 Oct; 49(10):1398-406. PubMed ID: 21964893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiangiogenic Therapy in Colorectal Cancer.
    Mody K; Baldeo C; Bekaii-Saab T
    Cancer J; 2018; 24(4):165-170. PubMed ID: 30119079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The evolving role of VEGF-targeted therapies in the treatment of metastatic colorectal cancer.
    Fakih M
    Expert Rev Anticancer Ther; 2013 Apr; 13(4):427-38. PubMed ID: 23432698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of tumor angiogenesis as a therapeutic target in colorectal cancer.
    Battaglin F; Puccini A; Intini R; Schirripa M; Ferro A; Bergamo F; Lonardi S; Zagonel V; Lenz HJ; Loupakis F
    Expert Rev Anticancer Ther; 2018 Mar; 18(3):251-266. PubMed ID: 29338550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Angiogenic Pathways in Colorectal Cancer: Complexities, Challenges and Future Directions.
    Khan K; Cunningham D; Chau I
    Curr Drug Targets; 2017; 18(1):56-71. PubMed ID: 25808652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The potential role of nintedanib in treating colorectal cancer.
    Rossi A; Latiano TP; Parente P; Chiarazzo C; Limosani F; Di Maggio G; Maiello E
    Expert Opin Pharmacother; 2017 Aug; 18(11):1153-1162. PubMed ID: 28649871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiangiogenic Tyrosine Kinase Inhibitors in Metastatic Colorectal Cancer: Focusing on Regorafenib.
    Papadimitriou M; Papadimitriou CA
    Anticancer Res; 2021 Feb; 41(2):567-582. PubMed ID: 33517262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic and pharmacodynamic evaluation of aflibercept for the treatment of colorectal cancer.
    Sanz-Garcia E; Saurí T; Tabernero J; Macarulla T
    Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):995-1004. PubMed ID: 25988772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biological Pathways Involved in Tumor Angiogenesis and Bevacizumab Based Anti-Angiogenic Therapy with Special References to Ovarian Cancer.
    Loizzi V; Del Vecchio V; Gargano G; De Liso M; Kardashi A; Naglieri E; Resta L; Cicinelli E; Cormio G
    Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28906427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patients.
    Tsai HL; Lin CH; Huang CW; Yang IP; Yeh YS; Hsu WH; Wu JY; Kuo CH; Tseng FY; Wang JY
    Int J Clin Exp Pathol; 2015; 8(2):1900-10. PubMed ID: 25973082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive tissue biomarkers for bevacizumab-containing therapy in metastatic colorectal cancer: an update.
    Marien KM; Croons V; Martinet W; De Loof H; Ung C; Waelput W; Scherer SJ; Kockx MM; De Meyer GR
    Expert Rev Mol Diagn; 2015 Mar; 15(3):399-414. PubMed ID: 25585649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological inhibition of MAGL attenuates experimental colon carcinogenesis.
    Pagano E; Borrelli F; Orlando P; Romano B; Monti M; Morbidelli L; Aviello G; Imperatore R; Capasso R; Piscitelli F; Buono L; Di Marzo V; Izzo AA
    Pharmacol Res; 2017 May; 119():227-236. PubMed ID: 28193521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beyond bevacizumab: new anti-VEGF strategies in colorectal cancer.
    Troiani T; Martinelli E; Orditura M; De Vita F; Ciardiello F; Morgillo F
    Expert Opin Investig Drugs; 2012 Jul; 21(7):949-59. PubMed ID: 22612461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiangiogenesis agents in colorectal cancer.
    Hubbard J; Grothey A
    Curr Opin Oncol; 2010 Jul; 22(4):374-80. PubMed ID: 20375894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.